Related Experiment Videos
Lipid abnormalities
1Indiana University School of Medicine, Wishard Memorial Hospital, Division of Infectious Diseases, Indianapolis, Indiana 46202-2879 , USA. mpdube@iupui.edu
Insights
Dyslipidemia is a significant issue for individuals with human immunodeficiency virus (HIV) on antiretroviral therapy, increasing cardiovascular disease risk. Management should follow guidelines, prioritizing lifestyle changes before medication to minimize drug interactions.
Area of Science:
- Cardiology
- Infectious Diseases
- Pharmacology
Background:
- Dyslipidemia presents a major clinical challenge in patients with human immunodeficiency virus (HIV) undergoing antiretroviral therapy (ART).
- Increased incidence of cardiovascular disease (CVD) is reported in the HIV-infected population on ART.
- Current evidence highlights the need for proactive management of lipid disorders in this demographic.
Purpose of the Study:
- To outline the clinical approach to managing dyslipidemia in HIV-infected individuals on ART.
- To emphasize the importance of adhering to established guidelines for cardiovascular risk assessment and treatment.
- To guide the selection of therapeutic interventions, prioritizing safety and minimizing drug interactions.
Main Methods:
- Evaluation and treatment strategies should align with the National Cholesterol Education Program (NCEP) guidelines.
- Nonpharmacological interventions, including dietary modifications, exercise, and management of other lifestyle risk factors, should be the primary approach.
- Pharmacological therapy should be considered only when nonpharmacological methods are insufficient, with careful selection of agents to avoid adverse drug interactions.
Main Results:
- Adherence to NCEP guidelines provides a structured framework for managing dyslipidemia in HIV patients.
- Lifestyle modifications are effective initial strategies for improving lipid profiles.
- The choice of lipid-lowering medications requires careful consideration of potential interactions with antiretroviral drugs.
Conclusions:
- Dyslipidemia management in HIV-infected individuals on ART is crucial for reducing cardiovascular risk.
- A stepwise approach, starting with lifestyle changes, is recommended.
- Pharmacological interventions should be chosen judiciously to ensure safety and efficacy, minimizing drug-drug interactions.
Abstract:
Dyslipidemia is an important clinical problem in individuals infected with human immunodeficiency virus (HIV) who are receiving antiretroviral therapy. Data suggest that increased cardiovascular disease is occurring in this population. HIV-infected individuals should undergo evaluation and treatment regimens based on the current National Cholesterol Education Program guidelines. In most situations, the first interventions should be nonpharmacological and should include diet, exercise, and management of other hygienic risk factors. If pharmacologic therapy becomes necessary, the choices of lipid-lowering agents should be limited to agents with the least likelihood of adverse drug interactions.